Expression of Programmed Cell Death Ligand 1 and Associated Lymphocyte Infiltration in Olfactory Neuroblastoma.

Autor: London NR Jr; Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, Maryland, USA., Rooper LM; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Bishop JA; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA., Xu H; Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Bernhardt LJ; Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Ishii M; Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Hann CL; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Taube JM; Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Izumchenko E; Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Gaykalova DA; Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Gallia GL; Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Electronic address: ggallia1@jhmi.edu.
Jazyk: angličtina
Zdroj: World neurosurgery [World Neurosurg] 2020 Mar; Vol. 135, pp. e187-e193. Date of Electronic Publication: 2019 Nov 27.
DOI: 10.1016/j.wneu.2019.11.112
Abstrakt: Background: Programmed cell death ligand 1 (PD-L1) is a transmembrane glycoprotein that interacts with the receptor programmed cell death 1 (PD-1) to suppress T-cell activation, reduce adjacent tissue damage, and promote tolerance to self-antigens. Tumors may express PD-L1 as a mechanism to evade immune detection. Recent clinical trials have demonstrated the efficacy of PD-L1/PD-1 antagonists through activation of tumor-infiltrated CD8 + T cells. The aim of this study was to determine the expression pattern of PD-L1 and PD-1 in olfactory neuroblastoma (ONB) tumor cells and to determine the presence of PD-1 + and CD8 + lymphocytes in the ONB immune microenvironment.
Methods: Immunohistochemistry for expression of PD-L1, PD-1, and CD8 was performed on paraffin-embedded ONB tissue.
Results: Of the 10 primary site ONB samples, 4 demonstrated positive PD-L1 expression. Of PD-L1 + tumors, the 2 highest expressing samples were found to contain PD-1 + tumor cells. Of the 4 available metastatic samples, all of which arose from PD-L1 - primary site ONB, 3 were positive for PD-L1 and contained PD-1 + tumor cells. PD-L1 + primary and metastatic tumors also demonstrated increased PD-1 + infiltrating lymphocytes in the tumor and stroma (11.6- and 4.62-fold increase) compared with PD-L1 - samples (P < 0.05 and P = 0.068 respectively). PD-L1 + specimens demonstrated increased CD8 + lymphocytes in the tumor and stroma (7.46- and 2.14-fold increase) compared with PD-L1 - tumors (P < 0.05 for both).
Conclusions: These data demonstrate that a proportion of ONB primary and metastatic tumors express PD-L1 and possess an associated tumor and stromal infiltrate of PD-1 + and CD8 + lymphocytes.
(Copyright © 2019 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: